Facing the first fine in its 29-year history, the drug maker Genzyme turned to Covington & Burling and Hogan Lovells for counsel in striking a proposed settlement with the federal government over allegedly contaminated drugs, court records show.
Under the terms of the proposed consent decree, Cambridge, Mass.–based Genzyme, which specializes in expensive drugs aimed at treating rare genetic disorders, will pay a $175 million penalty and submit to a strict regime of government oversight that could last up to eight years, according to the Boston Globe and The Associated Press.
